Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.

Maureen M O'Brien Lingyun Ji Nirali N Shah Susan R RheingoldDeepa BhojwaniConstance M YuanXinxin XuJoanna S Yi Andrew C Harris Patrick A BrownMichael J BorowitzOlga MilitanoJohn KairallaMeenakshi DevidasElizabeth A RaetzLia Gore Mignon L Loh

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

InO is effective and well tolerated in heavily pretreated children and adolescents with R/R CD22-positive B-ALL. SOS after hematopoietic stem-cell transplantation and prolonged cytopenias were notable. CD22 modulation was identified as a mechanism of resistance. Expanded study of InO combined with chemotherapy is underway.

Keyphrases

acute lymphoblastic leukemia
allogeneic hematopoietic stem cell transplantation
acute myeloid leukemia
randomized controlled trial
young adults
palliative care
nk cells
open label
diffuse large b cell lymphoma
squamous cell carcinoma
locally advanced
multiple myeloma
study protocol